Derm Cases · General Medicine
OSCE — Alopecia & Hair Disorders
Eight-minute OSCE station on Alopecia & Hair Disorders: focused history, examination priorities, investigations, emergency and definitive management.
On this page
Study tools
Target exams
Brief (to candidate)
You will assess a patient with a presentation consistent with Alopecia & Hair Disorders.
You have 8 minutes to take a focused history, outline examination, investigations, and management including red flags.
Clinical context
Hair loss (alopecia) is the single most psychologically charged dermatological presentation. The pivotal skill is the scarring vs non-scarring distinction: non-scarring (reversible — androgenetic, alopecia areata, telogen effluvium, anagen effluvium, traction, trichotillomania, tinea capitis) preserves the follicle and is potentially recoverable, whereas scarring (cicatricial) (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, discoid lupus, folliculitis decalvans, pseudopelade) destroys follicular stem cells and is permanent and irreversible. Androgenetic alopecia (miniaturisation by dihydrotestosterone via 5-alpha-reductase type II) is graded by the Hamilton-Norwood scale in men and the Ludwig scale in women.
[3]Candidate tasks
- Clarify onset, severity, associated features, and red-flag symptoms.
- State focused examination priorities.
- List first-line investigations and any named score/criteria.
- Give immediate resuscitation steps.
- Outline definitive management with doses/routes where standard.
- Name complications and disposition (ward / HDU / theatre / discharge safety-net).
- Mention one special-population modifier (pregnancy, child, elderly, CKD).
Examiner checklist
| Domain | Pass behaviours |
|---|---|
| Definition | Correct working diagnosis language |
| Assessment | Focused, prioritised, red flags sought |
| Investigations | Appropriate first-line + interpretation |
| Emergency care | ABC / time-critical actions first |
| Definitive care | Specific drugs/procedures, not generic phrases |
| Safety | Patchy non-scarring hair loss with exclamation-mark hairs — alopecia areata; grade extent and screen for autoimmune associations |
| Safety | Progressive bitemporal recession and vertex thinning in a man — androgenetic alopecia; grade and counsel |
| Safety | Diffuse shedding two to three months after pregnancy, illness, surgery or crash dieting — telogen effluvium; identify the trigger and reassure |
| Communication | Clear plan and safety-netting |
Model outline
Lead with the working diagnosis and life threats. Resuscitate before definitive tests when unstable. Use guideline-standard therapy with named agents and doses. Document escalation criteria and follow-up. A safe candidate is specific, structured, and never delays critical care for non-urgent imaging.[1]
References4ShowHide
- [1]King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial Lancet, 2023.PMID 37062298
- [2]Seyed Jafari SM, Starace M, Katoulis A, et al. Management of classic lichen planopilaris: The EADV task force on hair diseases position statement J Eur Acad Dermatol Venereol, 2026.PMID 41848299
- [3]Choi J, Ilan I, Tian JN, et al. Central Centrifugal Cicatricial Alopecia: A Survey of Treatment Practices Among Dermatology Residents and Attending Physicians Cureus, 2025.PMID 41122576
- [4]Afifi L, Oparaugo NC, Hogeling M. Review of traction alopecia in the pediatric patient: Diagnosis, prevention, and management Pediatr Dermatol, 2021.PMID 34467569